Emergent BioSolutions, Inc., to renovate East Baltimore facility

Emergent BioSolutions, Inc., has announced that it will undergo a $16.1 million renovation project at its East Baltimore biotechnology manufacturing facility.

The designs for the 55,000 square-foot facility, which Emergent BioSolutions, Inc., bought from the MdBio Foundantion for $7.85 million, have been completed, BizJournals.com reports.

Known for developing vaccines and antibodies, the Rockville, Maryland-based biopharmaceutical company is planning to manufacture anthrax vaccines at the site.

Emergent BioSolutions, Inc., currently manufactures BioThrax, the only FDA-licensed vaccine available for pre-exposure protection against the anthrax infection. To date, more than 10 million doses have been administered to more than 2.5 million individuals.

Founded by the BioPort Corporation in 2004, Emergent BioSolutions, Inc., also produces vaccines for typhoid and hepatitis B, and is currently in development for a group B streptococcus vaccine.

The biopharmaceutical company is recycling 97 percent, or 192 tons of debris, from the demolished building. The new facility will incorporate disposable manufacturing technology and has obtained a Leadership in Energy and Environmental Design Silver certification, BizJournal.com reports.

Emergent BioSolutions, Inc., has chosen Baltimore’s Whiting-Turner Contracting Co. for the renovation project at its East Baltimore biotechnology manufacturing facility, according to BizJournal.com. Construction has started and is anticipated to be completed by the end of 2011.